Mazdutide

Mazdutide is a dual-receptor agonist that acts on both the GLP-1 receptor and the glucagon receptor. It is also known as IBI362 or LY3305677, and it is an analog of oxyntomodulin, a naturally occurring peptide involved in appetite and metabolism regulation.

In practical terms, mazdutide is being developed as a metabolic medicine designed to support weight management and improve blood sugar control. Because it works through two pathways at once, it has attracted strong interest in obesity and diabetes research.

How Mazdutide Works

Mazdutide mimics the action of GLP-1 while also stimulating the glucagon receptor. The GLP-1 side of the mechanism helps reduce appetite, slow gastric emptying, and improve insulin secretion, while glucagon receptor activation may increase energy expenditure and support fat loss.

This dual action is what makes mazdutide different from standard GLP-1 medicines. Rather than focusing only on appetite and glucose regulation, it may also influence metabolic rate and body composition, which is why researchers view it as a next-generation obesity and diabetes treatment.

Clinical Research

Clinical studies have shown encouraging results for body weight reduction. A phase 2 randomized controlled trial reported that once-weekly mazdutide was well tolerated over 24 weeks and produced clinically meaningful weight loss compared with placebo in Chinese adults with overweight or obesity.

Drugs.com summarizes additional phase 2 findings showing average weight reductions of 7.21% after 24 weeks in one study, with higher doses producing greater weight loss. The same report also notes improvements in waist circumference, body mass index, blood pressure, liver fat, lipid levels, insulin sensitivity, transaminases, and serum uric acid.

More recent public reporting indicates that a phase 3 result released in 2025 showed clinically relevant reductions in body weight in Chinese adults with overweight or obesity, and the drug was approved for marketing in China in June 2026.

Uses and Potential Benefits

Mazdutide is mainly being developed for obesity and type 2 diabetes. Its appeal comes from the possibility of combining weight loss, glucose control, and broader metabolic improvements in a single weekly injection.

Potential benefits discussed in the literature include:

• Appetite reduction.

• Significant body weight loss.

• Better glucose regulation.

• Improved insulin sensitivity.

• Lower waist circumference.

• Possible improvement in liver fat and lipid markers.